Macular Edema, Diabetic Clinical Trial
Official title:
A Phase 2, Randomized, Double-masked, Placebo-controlled, Parallel Group, Multi-center Study To Compare The Efficacy And Safety Of A Chemokine Ccr2/5 Receptor Antagonist (Pf-04634817) With That Of Ranibizumab In Adult Subjects With Diabetic Macular Edema
The study hypothesis under test is that administration of the CCR2/5 antagonist has the potential to be as effective as the current treatment options for subjects with diabetic macular edema. The current treatment option for these subjects is an injection directly into the eye, while this CCR2/5 antagonist would be an oral drug which has the potential to be just as effective. This CCR2/5 antagonist also has a broader anti-inflammatory potential and might be able to provide an alternative mechanism to treat Diabetic Macular Edema.
Study recruitment was stopped on April 9, 2015. This decision was taken for business reasons due to changes in the prioritization of the drug development portfolio. This decision was not as a result of any evolving safety, efficacy issue or changes in the risk:benefit assessment of this product or regulatory interactions. ;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT02788877 -
Treat-and-extend Regimen of Aflibercept in Diabetic Macular Edema (VIBIM Study)
|
Phase 4 |